A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

(2011) W. P. Yong et al.   ANNALS OF ONCOLOGY

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

(2011) A R A Razak et al.   BRITISH JOURNAL OF CANCER

Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue

(2011) V. Novotny-Diermayr et al.   MOLECULAR CANCER THERAPEUTICS

Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

(2010) Maryam Fouladi et al.   JOURNAL OF CLINICAL ONCOLOGY

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

(2010) V. Novotny-Diermayr et al.   MOLECULAR CANCER THERAPEUTICS

Epigenetic Modifiers: Basic Understanding and Clinical Development

(2009) R. L. Piekarz et al.   CLINICAL CANCER RESEARCH

Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications

(2009) D. S. Schrump   CLINICAL CANCER RESEARCH